[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
May 2006

Topical Calcineurin Inhibitors for Atopic Dermatitis: Balancing Clinical Benefit and Possible Risks

Arch Dermatol. 2006;142(5):633-637. doi:10.1001/archderm.142.5.633

This editorial has been written at the request of the National Eczema Association for Science and Education (NEASE), San Rafael, Calif. The purpose is to provide an objective, independent view of the evidence surrounding the effectiveness and possible adverse effects of topical calcineurin inhibitors (TCIs) in response to the recent US Food and Drug Administration (FDA) concerns.1 This editorial is meant for patients with atopic dermatitis (AD) and their health care providers.